All In Biotech

Drug Trial Radar · NCT05584709

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

34

Planned (sponsor's estimate)

Start

Mar 2023

Primary completion

Aug 2025

Study completion Oct 2025

Sponsor

Lead sponsor
Sorrento Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1b, single-center, open-label, dose-finding trial designed to identify the Recommended Phase 2 Dose (RP2D) of STI 6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with any advanced solid tumor. The patients that will be treated with STI-6129 in this trial are advanced solid tumor patients who have received prior lines of treatment.

Conditions

  • Advanced Solid Tumor

Interventions

  • STI-6129Biological

    Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events by type, frequency, severity, and causality (safety)Time frame: Baseline through study completion at up to approximately 24 months
  2. Incidence of serious adverse events by type, frequency, severity, and causality (safety)Time frame: Baseline through study completion at up to approximately 24 months
  3. Incidence of dose-limiting toxicities (safety)Time frame: Baseline through study completion at up to approximately 24 months
  4. Incidence of neurotoxicity (safety)Time frame: Baseline through study completion at up to approximately 24 months
  5. Incidence of laboratory abnormalities (safety)Time frame: Baseline through study completion at up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.